secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001628280-24-046513
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Q3 revenue $11.2M (+44% QoQ); HEPZATO adoption grows; debt-free after warrant exercise
--------------------------------------------------------------------------------

- Q3 total revenue $11.2M (vs $0.4M prior year); HEPZATO $10.0M, CHEMOSAT $1.2M.
- Activated 12 HEPZATO treatment centers in U.S.; additional centers in training pipeline.
- Ended Q3 with $14.0M cash; quarterly cash burn $3.6M.
- Post-Q3: paid $2.8M final Rosalind note; ~$25M from Tranche B warrant exercise; no debt.
- Advancing HEPZATO programs for liver-dominant colorectal and breast cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828024046513/0001628280-24-046513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828024046513/dcth-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer